Opinion|Videos|September 4, 2024
Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please highlight the study design, efficacy, and safety data of the phase 3 DIPPER trial.
- What are your thoughts on the data and how might this impact the current treatment landscape?
Advertisement
Related to this article
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dive Into Key Data and Presentations From EHA 2026
4
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
5